Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients with Refractory Hematologic Malignancies

BACKGROUND: RAS/RAF/MAPK activation (mutational or non-mutational) is a key pathway for survival and proliferative advantage of leukemic cells. Salirasib is an oral RAS inhibitor that causes dislocation of RAS by competing directly with farnesylated RAS in binding to its putative membrane binding pr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Lymphoma Myeloma Leuk
Main Authors: Badar, Talha, Cortes, Jorge E, Ravandi, Farhad, O’Brien, Susan, Verstovsek, Srdan, Garcia-Manero, Guillermo, Kantarjian, Hagop, Borthakur, Gautam
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4509631/
https://ncbi.nlm.nih.gov/pubmed/25795639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2015.02.018
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki